Association of Type 2 Diabetes Risk with Some Anthropometric Measurements in Obese Adults

Main Article Content

Nazal Bardak Perçinci

Keywords

Obesity, Type 2 Diabetes, FINRISK

Abstract

Type 2 diabetes can be defined as an insidious disease that can last for years without symptoms. Disease In type 2 diabetes, insulin resistance and insulin secretion deformation are predominant and account for about 90-95% of all diabetics (5). The major disadvantage of delayed diagnosis is the increased risk of complications. The management of risk factors and risk factors that can be considered as a finding can prevent the disease or keep it uncomplicated (6). A total of 95 obese women adults with a mean age of 33.65 ± 1.62 years were included in this study. All cases were women. The Finnish Type-2 DM Risk Scale (FINRISK) was used to determine the risk of type 2 diabetes. FINDRISK (diabetes risks) scoring results of the participants are given in Table 2. According to this distribution, 15.8% of the participants were low risk, 26.3% were mild risk, 28.4% were medium risk, 13.7% were high risk and 15.8% were carries a very high risk. When body weight and risk scoring were evaluated, body weight was found to be statistically significant between the low-risk group and the high-risk group and the low-risk group and the medium-risk groups (<0.001). The difference between BMI values ​​between low risk group and medium risk group, low risk group and mild risk group and between high risk and very high risk groups were found to be statistically significant (<0.001). No statistical significance was found between height and body fat percentage (%) values. The difference between waist circumference, hip circumference and waist / hip ratio values ​​between low risk group and medium risk group, between low risk group and high risk group, and between mild risk and high risk groups were statistically significant (<0.001).

Abstract 151 | PDF Downloads 347

References

1. World Health Organization, “Obesity: Preventing and Managing The Global Epidemic”, Report of a WHO Conculcation, WHO Technical Report Series 894, Geneva, 2000.
2. Turkey Endocrinology and Metabolism Association (SEMT) Diagnosis of Diabetes Mellitus and its Complications, Treatment and Monitoring Guide-2017. Downloaded from http://temd.org.tr/admin/uploads/tbl_kilavuz/DI-YABET2017_web.pdf on 2/12/2019.
3. Satman I, Omer B, Tutuncu Y, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013; 28 (2): 169–80.
4. Coşansu G. Diabetes: A Global Epidemic. Okmeydanı Journal of Medicine 2015; 31 (Supplementary issue): 1-6.
5. American Diabetes Association. Prevention or delay of type 2 diabetes. Sec.5. Diabetes Care 2015; 38: 31-2.
6. The DPP Study Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care 2000; 23 (11): 1619-29.
7. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemi K, Hämäläinen H, Härkönen P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study Group. Lindström J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003 Mar; 26 (3): 725-31.
8. Makrilakis K, Liatis S, Grammatikou S, Perrea D, et al. Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece. Diabetes Metab 2011; 37 (2): 144-151.
9. Hellgren MI, Petzold M, Björkelund C, Wedel H, et al. Feasibility of the FINDRISC questionnaire to identify individuals with impaired glucose tolerance in Swedish primary care. A cross-sectional population-based study. Diabetes Med 2012; 29 (12): 1501-5.
10. Costa B, Barrio F, Piol JL, Cabré JJ, et al. The HbA1c diagnosis reduces the ability of the Finnish Diabetes Risk Score (FINDRISC) to screen for glucose abnormalities within a real-life primary healthcare preventive strategy. BMC Medicine 2013; 11: 45.
11. Tarı Selçuk K, Determination of Type 2 Diabetes Risk in 45-74 Age Individuals in Bigadiç, PhD thesis, İzmir: Dokuz Eylül University; 2013.
12. Memiş S, Gökçe S, Gündoğmuş EE, Coşkunırmak D. Evaluation of diabetes risks of Health School students with type-2 diabetes in their families. Nursing forum journal of diabetes, obesity and hypertension; July-December (2014); Volume: 6, Issue: 2.
13. Aksakoglu G. Correlation and regression computation methods In: Aksakoglu G, eds. Research and analysis in health. 2. Printing. İzmir: DEÜ Rectorate Printing House; 2006. p. 283-90.
14. International Diabetes Federation 2013. http://www.idf.org/signs-and-symptoms-diabetes. Accessed on 06.12.2019.
15. WHO, 10 facts about diabetes, November 2014. http://www.who.int/features/factfiles/diabetes/facts/en/ (Accessed 06.12.2019).
16. International Diabetes Federation 2013. http://www.idf.org/signs-and-symptoms-diabetes. Accessed on 19.11.2013.
17. Coşansu G, Çelik SG, Olgun N, Özcan Ş, Demir HG. Determination of risk factors for Type-2 Diabetes in adults: an example of a community-based study. 49. National diabetes congress 1721 April 2013; 303. www.diabetes congress2013org. Access Date: 05.12.2019.
18. Taşdemir-Koçak HST, Öncel S, Zincir H, Sevig Ü. Determination of type 2 diabetes risk ratio and healthy lifestyle behaviors among classroom teachers. Public Health Activities - HASUDER, 16th National Public Health Congress, 2013.
19. Makrilakis K, Liatis S, Grammatikou S, Perrea D, et al. Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece. Diabetes Metab 2011; 37 (2): 144-151.
20. Chiasson JL, Josse RG, Gomis R, et al. STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomizedtrial. Lancet. 2002; 359 (9323): 2072-7.
21. Tankova T, Chakarova N, Atanassova I et al. Evaluation of the Finnish Diabetes Risk Score as a screening tool for impaired fasting glucose, impaired glucosetolerance and undetected diabetes. Diabetes Res Clin Pract. 2011; 92 (1): 46-52.
22. Costa B, Barrio F, Piñol JL, et al. The HbA1c diagnosis reduces the ability of the Finnish Diabetes Risk Score (FINDRISC) to screen for glucose abnormalities. BMC Med. 2013; 11: 45.